The Competition Commission of India has imposed a Rs 40 lakh penalty on Goldman Sachs AIMPL for not notifying the regulator about a deal involving optionally convertible debentures issued by Biocon Biologics. CCI ruled the deal was strategic and required prior approval.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Qp1iXRJ
via IFTTT
No comments:
Post a Comment